NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries

Stopped The study was stopped early (n=35) enabling the data to guide design of the subsequent clinical study.

Conditions

• Corneal Persistent Epithelial Defect

Interventions

• DRUG: Nexagon® (lufepirsen) High Dose Concentration
• DRUG: Nexagon® (lufepirsen) Low Dose Concentration
• DRUG: Vehicle
• DRUG: Open-label Nexagon® (lufepirsen)

Sponsor

Glaukos Corporation

Collaborators

• [object Object]